|
[1]
|
Richardson, L.C., Henley, S.J., Miller, J.W., et al. (2016) Patterns and Trends in Age-Specific Black-White Differences in Breast Cancer Incidence and Mortality—United States, 1999-2014. Morbidity and Mortality Weekly Report, 65, 1093-1098. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Fan, L., Strasser-Weippl, K., Li, J.J., et al. (2014) Breast Cancer in China. The Lancet Oncology, 15, e279-e289. [Google Scholar] [CrossRef]
|
|
[3]
|
王永南, 李文萍, 于海云, 万舰. 老年乳腺癌术后辅助化疗对预后的影响[J]. 岭南现代临床外科, 2017, 17(2): 198-201.
|
|
[4]
|
王祥宇. 老年女性乳腺癌的临床病理特征及预后分析[D]: [硕士学位论文]. 石家庄: 河北医科大学, 2021.
|
|
[5]
|
赵卫红, 徐兵河, 李青, 等. 70岁以上老年女性乳腺癌患者的特点和预后分析[J]. 中华肿瘤杂志, 2006(5): 385-388.
|
|
[6]
|
严珊珊, 王永南. 老年乳腺癌的临床病理特点和预后的特点[J]. 岭南现代临床外科, 2019(6): 689-693.
|
|
[7]
|
Gennari, R., Curigliano, G., Rotmensz, N., et al. (2004) Breast Carcinoma in Elderly Women: Features of Disease Presentation, Choice of Local and Systemic Treatments Compared with Younger Postmenopausal Patients. Cancer, 101, 1302-1310. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
蔡建强, 等. 65岁以上老年乳腺癌的治疗和预后[J]. 癌症杂志, 2000, 15(2): 179-183.
|
|
[9]
|
中国抗癌协会乳腺癌专业委员会. 中国抗癌协会乳腺癌诊治指南与规范(2021年版) [J]. 中国癌症杂志, 2021, 31(10): 954-1040.
|
|
[10]
|
李晓红. 紫杉类药物用于老年乳腺癌患者新辅助化疗疗效及不良反应分析[J]. 实用临床医药杂志, 2013, 17(15): 74-76.
|
|
[11]
|
曹原, 高军. 紫杉类药物新辅助治疗老年乳腺癌的疗效及不良反应分析[J]. 实用癌症杂志, 2019, 34(9): 1485-1487.
|
|
[12]
|
黄波, 林建山, 袁园园. 老年乳腺癌治疗中紫杉类药物新辅助治疗的疗效及不良反应[J]. 中国现代药物应用, 2020, 14(17): 188-190.
|
|
[13]
|
谢意程, 张海良. 老年乳腺癌治疗中紫杉类药物新辅助治疗的疗效及不良反应研究[J]. 北方药学, 2022(9): 138-140.
|
|
[14]
|
吕锋, 黄小娥, 鲁科斌. 蒽环类与紫杉类联合新辅助化疗治疗早期或局部晚期乳腺癌的疗效及对患者ER, PR和Her-2的影响[J]. 中国生化药物杂志, 2017, 37(3): 195-197.
|
|
[15]
|
孟凡军, 陈育标, 庄梅生. 早期乳腺癌保留乳房手术后全乳腺大分割与常规分割放疗的疗效和毒副反应比较[J]. 海南医学, 2017, 28(12): 2024-2025.
|
|
[16]
|
Gradishar, W.J. and Anderson, B.O. (2020) Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 18, 452-478.
|
|
[17]
|
徐兵河. 乳腺癌靶向治疗的临床进展和未来[J]. 中国肿瘤临床, 2017, 44(13): 625-629.
|
|
[18]
|
汪霖. 人类表皮生长因子受体2阳性肿瘤靶向药物研究进展[J]. 实用肿瘤学杂志, 2016, 30(3): 266-270.
|
|
[19]
|
Daniels, B., Kiely, B.E., Tang, M., et al. (2019) Trastuzumab Use in Older Patients with HER2-Positive Metastatic Breast Cancer: Outcomes and Treatment Patterns in a Whole-of-Population Australian Cohort (2003-2015). BMC Cancer, 19, 909. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Early Breast Cancer Trialists Collaborative Group (1998) Tamoxifen for Early Breast Cancer: An Overview of the Randomized Trials. The Lancet, 351, 1451-1467. [Google Scholar] [CrossRef]
|
|
[21]
|
江泽飞, 宋三泰, 孙燕. 乳腺癌内分泌治疗的基本原则和新动向——2006年美国NCCN乳癌内分泌治疗解读[J]. 临床药物治疗杂志, 2006, 4(2): 21-25.
|